Penfluridol for schizophrenia

The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study

“…A Cochrane review showed the safety and efficacy of penfluridol to be comparable with the depot formulation. As it was also better at 'keeping patients in treatment', penfluridol may help reduce adherence problems in patients who refuse depot formulations because of invasiveness [10,11]. Our results show that, overall, penfluridol showed a pattern of discontinuation similar to depot formulation.…”

The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study

“…A Cochrane review showed the safety and efficacy of penfluridol to be comparable with the depot formulation. As it was also better at 'keeping patients in treatment', penfluridol may help reduce adherence problems in patients who refuse depot formulations because of invasiveness [10,11]. Our results show that, overall, penfluridol showed a pattern of discontinuation similar to depot formulation.…”

Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis

“…(d) Antibiofilm effects of PF against 3 of biofilm-forming clinical isolates. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 versus the untreated control used for the treatment of schizophrenia (Soares & Lima, 2006). In our in vivo model, the dose of PF that we used was 20 mg/kg, which was relatively less than that of human use.…”

Penfluridol for schizophrenia

“…We found one review that met our inclusion criteria [3]. thiothixene), there were no differences in the medium term for needing antiparkinsonian medication (3 months to 1 year, N = 169, 4 RCTs, 1.20 CI 0.91 to 1.58, I 2 = 0%, p = 0.70) or for other sideeffects.…”

The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study

“…A Cochrane review showed the safety and efficacy of penfluridol to be comparable with the depot formulation. As it was also better at 'keeping patients in treatment', penfluridol may help reduce adherence problems in patients who refuse depot formulations because of invasiveness [10,11]. Our results show that, overall, penfluridol showed a pattern of discontinuation similar to depot formulation.…”

Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis

“…(d) Antibiofilm effects of PF against 3 of biofilm-forming clinical isolates. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 versus the untreated control used for the treatment of schizophrenia (Soares & Lima, 2006). In our in vivo model, the dose of PF that we used was 20 mg/kg, which was relatively less than that of human use.…”

Penfluridol for schizophrenia

“…We found one review that met our inclusion criteria [3]. thiothixene), there were no differences in the medium term for needing antiparkinsonian medication (3 months to 1 year, N = 169, 4 RCTs, 1.20 CI 0.91 to 1.58, I 2 = 0%, p = 0.70) or for other sideeffects.…”

The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study

“…A Cochrane review showed the safety and efficacy of penfluridol to be comparable with the depot formulation. As it was also better at 'keeping patients in treatment', penfluridol may help reduce adherence problems in patients who refuse depot formulations because of invasiveness [10,11]. Our results show that, overall, penfluridol showed a pattern of discontinuation similar to depot formulation.…”

Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis

“…(d) Antibiofilm effects of PF against 3 of biofilm-forming clinical isolates. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 versus the untreated control used for the treatment of schizophrenia (Soares & Lima, 2006). In our in vivo model, the dose of PF that we used was 20 mg/kg, which was relatively less than that of human use.…”

Penfluridol for schizophrenia

“…We found one review that met our inclusion criteria [3]. thiothixene), there were no differences in the medium term for needing antiparkinsonian medication (3 months to 1 year, N = 169, 4 RCTs, 1.20 CI 0.91 to 1.58, I 2 = 0%, p = 0.70) or for other sideeffects.…”